263 related articles for article (PubMed ID: 26927204)
1. Treatment Patterns and Health Care Costs for Age-Related Macular Degeneration in Japan: An Analysis of National Insurance Claims Data.
Kume A; Ohshiro T; Sakurada Y; Kikushima W; Yoneyama S; Kashiwagi K
Ophthalmology; 2016 Jun; 123(6):1263-8. PubMed ID: 26927204
[TBL] [Abstract][Full Text] [Related]
2. Incidence and Clinical Practice of Exudative Age-related Macular Degeneration: A Nationwide Population-Based Cohort Study.
Kido A; Miyake M; Tamura H; Hiragi S; Kimura T; Yoshida S; Takeuchi M; Ohtera S; Takahashi A; Ooto S; Kawakami K; Kuroda T; Tsujikawa A
Ophthalmol Sci; 2022 Jun; 2(2):100125. PubMed ID: 36249688
[TBL] [Abstract][Full Text] [Related]
3. Eye-related medicare costs for patients with age-related macular degeneration from 1995 to 1999.
Coleman AL; Yu F
Ophthalmology; 2008 Jan; 115(1):18-25. PubMed ID: 17572499
[TBL] [Abstract][Full Text] [Related]
4. [The treatment of the exsudative age-related macular degeneration with choroidal neovascular membrane, its possibilities and economical indexes].
Karel I
Cesk Slov Oftalmol; 2007 Sep; 63(5):311-9. PubMed ID: 17915581
[TBL] [Abstract][Full Text] [Related]
5. Incremental economic burden associated with exudative age-related macular degeneration: a population-based study.
Kim S; Park SJ; Byun SJ; Park KH; Suh HS
BMC Health Serv Res; 2019 Nov; 19(1):828. PubMed ID: 31718629
[TBL] [Abstract][Full Text] [Related]
6. The Clinical Effectiveness and Cost-Effectiveness of Screening for Age-Related Macular Degeneration in Japan: A Markov Modeling Study.
Tamura H; Goto R; Akune Y; Hiratsuka Y; Hiragi S; Yamada M
PLoS One; 2015; 10(7):e0133628. PubMed ID: 26214804
[TBL] [Abstract][Full Text] [Related]
7. Stroke rates after introduction of vascular endothelial growth factor inhibitors for macular degeneration: a time series analysis.
Campbell RJ; Bell CM; Paterson JM; Bronskill SE; Moineddin R; Whitehead M; Gill SS
Ophthalmology; 2012 Aug; 119(8):1604-8. PubMed ID: 22717458
[TBL] [Abstract][Full Text] [Related]
8. Economic implications of current age-related macular degeneration treatments.
Smiddy WE
Ophthalmology; 2009 Mar; 116(3):481-7. PubMed ID: 19157562
[TBL] [Abstract][Full Text] [Related]
9. Treatment patterns for neovascular age-related macular degeneration: analysis of 284 380 medicare beneficiaries.
Curtis LH; Hammill BG; Qualls LG; DiMartino LD; Wang F; Schulman KA; Cousins SW
Am J Ophthalmol; 2012 Jun; 153(6):1116-24.e1. PubMed ID: 22321802
[TBL] [Abstract][Full Text] [Related]
10. Age-related macular degeneration, anti-vascular endothelial growth factor agents, and short-term mortality: a postmarketing medication safety and surveillance study.
French DD; Margo CE
Retina; 2011 Jun; 31(6):1036-42. PubMed ID: 21836410
[TBL] [Abstract][Full Text] [Related]
11. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States.
Erie JC; Barkmeier AJ; Hodge DO; Mahr MA
Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701
[TBL] [Abstract][Full Text] [Related]
12. Prevalence and Incidence of Exudative Age-Related Macular Degeneration in South Korea: A Nationwide Population-Based Study.
Park SJ; Kwon KE; Choi NK; Park KH; Woo SJ
Ophthalmology; 2015 Oct; 122(10):2063-70.e1. PubMed ID: 26208437
[TBL] [Abstract][Full Text] [Related]
13. [Age-related macular degeneration: a socioeconomic time bomb in our aging society].
Schrader WF
Ophthalmologe; 2006 Sep; 103(9):742-8. PubMed ID: 16924447
[TBL] [Abstract][Full Text] [Related]
14. [Age-related macular degeneration--new options for therapy?].
Bornfeld N
Klin Monbl Augenheilkd; 2005 May; 222(5):379-80. PubMed ID: 15912453
[No Abstract] [Full Text] [Related]
15. Relative cost of a line of vision in age-related macular degeneration.
Smiddy WE
Ophthalmology; 2007 May; 114(5):847-54. PubMed ID: 17306878
[TBL] [Abstract][Full Text] [Related]
16. Rising trends in surgery for rotator cuff disease in Western Australia.
Thorpe A; Hurworth M; O'Sullivan P; Mitchell T; Smith A
ANZ J Surg; 2016 Oct; 86(10):801-804. PubMed ID: 27490156
[TBL] [Abstract][Full Text] [Related]
17. [Guidance for the treatment of neovascular age-related macular degeneration (AMD)].
Karska-Basta I; Kubicka-Trzaska A; Oleksy P; Romanowska-Dixon B
Przegl Lek; 2009; 66(11):972-5. PubMed ID: 20297641
[TBL] [Abstract][Full Text] [Related]
18. The cost-effectiveness of treatment of age-related macular degeneration: a review.
Kymes Steven M
Minerva Med; 2009 Feb; 100(1):69-78. PubMed ID: 19277005
[TBL] [Abstract][Full Text] [Related]
19. Patterns and costs associated with progression of age-related macular degeneration.
Schmier JK; Covert DW; Lau EC
Am J Ophthalmol; 2012 Oct; 154(4):675-681.e1. PubMed ID: 22835513
[TBL] [Abstract][Full Text] [Related]
20. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients.
Gomi F; Ohji M; Sayanagi K; Sawa M; Sakaguchi H; Oshima Y; Ikuno Y; Tano Y
Ophthalmology; 2008 Jan; 115(1):141-6. PubMed ID: 17582498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
